ArticleAmerican journal of Alzheimer's disease and other dementias2014
Synergistic epistasis of paraoxonase 1 (rs662 and rs85460) and apolipoprotein E4 genes in pathogenesis of Alzheimer's disease and vascular dementia.
Article in American journal of Alzheimer's disease and other dementias, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Revealing a Novel Landscape of the Association Between Blood Lipid Levels and Alzheimer's Disease: A Meta-Analysis of a Case-Control Study.Frontiers in aging neuroscience · 2019Pooled it
- Investigation of Paraoxonase-1 Genotype and Enzyme-Kinetic Parameters in the Context of Cognitive Impairment in Parkinson's Disease.Antioxidants (Basel, Switzerland) · 2023Article
- Changing demography and the challenge of dementia in India.Nature reviews. Neurology · 2021Review
- Vascular Dementia and Underlying Sex Differences.Frontiers in aging neuroscience · 2021Review
- Paraoxonase Role in Human Neurodegenerative Diseases.Antioxidants (Basel, Switzerland) · 2020Review
- Genetic architecture of common non-Alzheimer's disease dementias.Neurobiology of disease · 2020Review
- Evaluating the link between Paraoxonase-1 levels and Alzheimer's disease development.Minerva medica · 2019Review
- Altered High Density Lipoprotein Composition in Behavioral Variant Frontotemporal Dementia.Frontiers in neuroscience · 2018Article
- Organophosphate pesticides and PON1 L55M in Parkinson's disease progression.Environment international · 2017Article
- Genetics of vascular dementia - review from the ICVD working group.BMC medicine · 2017Review
- Assessment of paraoxonase 1 activity in patients with Alzheimer's disease and vascular dementia.American journal of Alzheimer's disease and other dementias · 2015Article
- Genetics and underlying pathology of dementia.Neuropsychology review · 2015Review
Corrections and comments
- Commented on by
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genetic polymorphism and epistasis play a role in etiopathogenesis of Alzheimer's disease (AD) and vascular dementia (VaD). In this case-control study, a total of 241 patients were included in the study to see the effect of paraoxonase 1 (PON1; rs662 and rs85460) and apolipoprotein E (ApoE) genes in altering the odds of having AD and VaD along with serum PON and lipid profile. The presence of at least 1 variant allele of rs662, but not rs85460, increased the risk of having AD by 1.8-fold (95% confidence interval [CI]: 0.97-3.40) and VaD by 3.09-fold (95% CI: 1.4-6.9). The interaction between PON1 genes (rs662 and rs85460) and ApoE genes showed synergistic epistasis in altering the odds of significantly having both AD and VaD. On the other hand, low serum level of high-density lipoprotein and low level of serum PON activity were found associated significantly (P ≤ .001 in both cases) only in patients with VaD as compared to healthy control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.